US2003166862A1PendingUtilityA1
Purified mammalian CTLA-8 antigens and related reagents
Est. expiryJun 14, 2013(expired)· nominal 20-yr term from priority
Inventors:Pierre GolsteinEric RouvierFrancois FossiezSerge LebecqueOdile DjossouJacques F. Banchereau
C07K 14/715A61K 38/00C07K 14/52C07K 16/244Y10S435/975
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
CTLA-8 antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A nucleic acid at least 95% identical to one encoding a mammalian CTLA protein or fragment thereof.
2 . The nucleic acid of claim 1 , wherein said encoding nucleic acid comprises a sequence of SEQ ID NO: 1, 3, 5, 7, or 9.
3 . A substantially pure primate CTLA-8 protein or peptide thereof.
4 . The protein or peptide of claim 3 , wherein said protein or peptide comprises a sequence of SEQ ID NO: 2, 4, 6, 8, or 10.
5 . The protein or peptide of claim 4 , wherein said protein or peptide induces a cell to secrete an inflammatory mediator.
6 . The protein or peptide of claim 5 , wherein said inflammatory mediator is IL-6; IL-8; and/or PGE2.
7 . A composition comprising a protein of claim 3 , and a pharmaceutically acceptable carrier.
8 . An antibody which specifically binds a mammalian CTLA-8 protein or peptide thereof.
9 . The antibody of claim 8 , wherein said antibody is raised against a peptide sequence of SEQ ID NO: 2, 4, 6, 8, or 10.
10 . The antibody of claim 9 , wherein said antibody is a monoclonal antibody.
11 . The antibody of claim 10 , wherein said antibody blocks a CTLA-8 induced secretion of an inflammatory mediator.
12 . The antibody of claim 10 , wherein said inflammatory mediator is IL-6; IL-8; and/or PGE2.
13 . An antibody of claim 10 , wherein said antibody is labeled.
14 . A kit comprising:
a) a nucleic acid at least 95% identical to one encoding a mammalian CTLA-8 protein or peptide; b) a substantially pure mammalian CTLA-8 protein or fragment; or c) an antibody or receptor which specifically binds a mammalian CTLA-8 protein.
15 . The kit of claim 14 , wherein said encoding nucleic acid comprises a sequence of SEQ ID NO: 1, 3, 5, 7, or 9.
16 . The kit of claim 14 , wherein said protein or fragment is selected from the group consisting of:
a) a protein or peptide from a mammal, including a rat or human; b) a protein or peptide comprising at least one polypeptide segment of SEQ ID NO: 2, 4, 6, 8, or 10; and c) a protein or peptide which exhibits a post-translational modification pattern distinct from a natural mammalian CTLA-8 protein.
17 . The kit of claim 14 comprising an antibody or receptor, wherein:
a) said CTLA-8 protein from a mammal, including a mouse or human;
b) said antibody is raised against a peptide sequence of SEQ ID NO: 2, 4, 6, 8, or 10;
c) said antibody is a monoclonal antibody; or
d) said antibody is labeled.
18 . A method of modulating physiology or development of a cell comprising contacting said cell with an agonist or antagonist of a mammalian CTLA-8 protein.
19 . A method of claim 18 , wherein said antagonist is an antibody against a mammalian CTLA-8 protein.
20 . A method of modulating CTLA-8 induced secretion of an inflammatory mediator from a cell in a tissue comprising the step of contacting said tissue with:
a) an antibody which specifically binds to a mammalian CTLA-8; or b) a substantially pure CTLA-8 protein or peptide thereof.
21 . The method of claim 20 , wherein said inflammatory mediator is selected from the group consisting of: IL-6; IL-8; and/or PGE2.
22 . The method of claim 20 , wherein said cell is selected from the group consisting of:
a) a synovial cell; b) an endothelial cell; c) an epithelial cell; d) a fibroblast cell; or e) a carcinoma cell.Join the waitlist — get patent alerts
Track US2003166862A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.